

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-31 (Cancelled).

Claim 32 (Previously Presented): A method for the treatment of Parkinson's disease comprising:  
administering to a patient in need thereof a composition for the treatment of Parkinson's disease, said composition comprising 2-[3-[4[-(3-chlorophenyl)-1-piperazinyl] propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4,-triazol-3(4H)-one or a pharmaceutically acceptable salt thereof.

Claim 33 (Previously Presented): The method according to claim 32 further comprising simultaneously administering L-dopamine to said patient.

Claim 34 (Previously Presented): The method according to claim 32 wherein said step of administering to said patient further comprises providing a daily dose of said composition totaling between about 100 mg and about 800 mg.

Claim 35 (Previously Presented): The method according to claim 32 wherein said step of administering to said patient further comprises providing a daily dose of said composition totaling between about 300 and about 600 mg.

Claim 36 (Previously Presented): The method according to claim 32 further comprising administering said composition in two to three single doses.

Claim 37 (Previously Presented): The method according to claim 32 wherein said step of administering to said patient further comprises administering

said composition in one or more single doses each of about 100 mg to about 200 mg.

Claim 38 (Previously Presented): The method according to claim 32 wherein said composition is in tablet form intended for oral intake.

Claim 39 (Previously Presented): The method according to claim 32 further comprising administering a composition comprising a pharmaceutical agent selected from the group of pharmaceutical agents consisting of caffeine, acetyl salicylic acid or combinations thereof.

Claim 40 (Withdrawn): The method according to claim 32 wherein said composition further comprises 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[3,4-a]pyridin-3(2H)-one.

Claim 41 (Withdrawn): The method according to claim 40 wherein said composition further comprises at least one antihistamine or a pharmaceutically acceptable salt thereof.

Claim 42 (Withdrawn): The method according to claim 41, wherein said antihistamine comprises cetirizine or one of its pharmaceutically acceptable salts.